In 1985, Takeda formed TAP Pharmaceuticals Inc. in the U.S. in a 50:50 joint venture with Abbott Laboratories. TAP began marketing the prostate cancer treatment Lupron® in the same year.
Tsukuba Research Laboratories became Takeda's second research base, coupled with the one in Osaka. These laboratories conduct basic research using cutting-edge technologies.
Effective for one full month with a single dosing, this was the successor to Lupron®. It is now sold in around 80 countries worldwide, and is considered a gold standard therapy for prostate cancer. Also on the market now are 4 Month Depot (one dosing every 4 months) in the U.S.
The success of Lupron Depot® and Prevacid® helped Takeda solidify its position as a global pharmaceutical manufacturer. These two drugs each had worldwide sales exceeding $1 billion and had given us a firm business foundation in the U.S. and Europe. In recent years, we further solidified our overseas bases to prepare for our new blockbuster drugs and aimed at greater business expansion.
Established as a special subsidiary, LI Takeda operates under the management mission of "being a friendly company for workers with disabilities." It was the first company of its kind in the Japanese pharmaceutical industry.
Candesartan is an angiotensin II receptor antagonist licensed in around 60 countries worldwide.
As a wholly owned pharmaceutical marketing subsidiary, it was established in London.
As a pharmaceutical manufacturing plant, Takeda Ireland Ltd has been working to meet the sharp increase in demand in the United States and Europe.
Takeda America Research & Development Center Inc., a pharmaceutical development company was established
Takeda America Holdings, Inc. , a holding company for our U.S. pharmaceutical business was established
Takeda Pharmaceuticals America, Inc., a wholly owned pharmaceutical marketing company in the U.S., began marketing the insulin sensitizer Actos® (pioglitazone) in the next year.
Takeda Europe Research & Development Centre Ltd., (now Takeda Global Research ® Development Centre (Europe), Ltd. ) a pharmaceutical development company was established in the U.K.
Actos® improves insulin resistance and reduce blood sugar levels.
Date of Preparation : December 2017